StockData

Longeveron vs ProKidney

LGVN and PROK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGVN and PROK compare

ProKidney is the larger company, worth 4.0 times as much as Longeveron ($316M against $79.4M).

ProKidney grew revenue faster over the last twelve months (4.2% versus −18.9% for Longeveron).

Longeveron keeps more of each dollar of sales as profit, with a net margin of −1922% compared with −13327% at ProKidney.

Longeveron scores higher on the StockData Score (5 against 4 for ProKidney), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGVNPROK
Size and price
Market cap$79.4M$316M
Share price$2.49$1.04
Change, 1 year−64.8%−61.0%
Change, 5 years−99.8%−89.5%
Beta (5Y)1.241.30
Employees37231
StockData Score
Total score5 (better)4
Valuation score00
Growth score00
Performance score00
Health score5 (better)4
Dividend score00
Valuation
P/S68.1× (better)408×
P/B16.9×–
FCF yield−22.9% (better)−53.1%
Growth
Revenue growth (TTM)−18.9%4.2% (better)
Revenue growth, 5Y average−26.6%–
Profitability
Gross margin66.4%–
Operating margin−2021% (better)−24830%
Net margin−1922% (better)−13327%
FCF margin−1560% (better)−21655%
Return on equity−305%–
Financial health
Debt / equity0.00–
Interest coverage–−10690.8×
Current ratio1.255.04 (better)
Altman Z-score−17.08−5.65 (better)
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield–−5.4%
Shareholder yield0.00% (better)−5.4%
Ownership
Held by institutions1.5%16.1%
Held by insiders43.8%62.9%
Insider net buying, 12 months–−$1.1M
Short interest, % of float0.88%21.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.